Jasmin Choi, Lane Burgette, Katherine Nameth, Katherine E Watkins, Karen Chan Osilla
{"title":"Examining how support persons' buprenorphine attitudes and their communication about substance use impacts patient well-being.","authors":"Jasmin Choi, Lane Burgette, Katherine Nameth, Katherine E Watkins, Karen Chan Osilla","doi":"10.1080/00952990.2024.2417820","DOIUrl":null,"url":null,"abstract":"<p><p><i>Background:</i> While social support benefits those in treatment for opioid use disorder, it is unclear how social support impacts patient outcomes.<i>Objectives:</i> This study examines how support person attitudes toward buprenorphine and their communication about substance use are associated with the well-being of patients receiving buprenorphine treatment.<i>Methods:</i> We analyzed cross-sectional baseline data from 219 buprenorphine patients (40% female) and their support persons (72% female). Patients were recruited from five community health centers and asked to nominate a support person. Patient outcomes included symptoms of depression, anxiety, impairment due to substance use, and perceived social support. Support persons predictors included their attitudes toward buprenorphine from four statements (e.g. \"Buprenorphine is just replacing one drug for another\") and communication using two items (e.g. comfort and effectiveness discussing substance use).<i>Results:</i> More stigmatizing attitudes, such as believing patients should quit on their own without medication, were associated with increased patient substance use-related impairment (F = 4.53, <i>p</i> = .01). Effective communication was associated with lower patient depression (F = 10.15, <i>p</i> < .001), anxiety (F = 4.73, <i>p</i> = .001), lower impairment (F = 6.46, <i>p</i> < .001), and higher perceived social support (F = 3.68, <i>p</i> = .007).<i>Conclusions:</i> This study highlights how support person attitudes and communication dynamics significantly affect the mental health and impairment of individuals receiving buprenorphine treatment. Interventions that reduce stigma and promote effective communication between patients and their loved ones could enhance treatment outcomes and overall well-being among patients with OUD.</p>","PeriodicalId":48957,"journal":{"name":"American Journal of Drug and Alcohol Abuse","volume":" ","pages":"137-147"},"PeriodicalIF":2.7000,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Drug and Alcohol Abuse","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/00952990.2024.2417820","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/30 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PSYCHOLOGY, CLINICAL","Score":null,"Total":0}
引用次数: 0
Abstract
Background: While social support benefits those in treatment for opioid use disorder, it is unclear how social support impacts patient outcomes.Objectives: This study examines how support person attitudes toward buprenorphine and their communication about substance use are associated with the well-being of patients receiving buprenorphine treatment.Methods: We analyzed cross-sectional baseline data from 219 buprenorphine patients (40% female) and their support persons (72% female). Patients were recruited from five community health centers and asked to nominate a support person. Patient outcomes included symptoms of depression, anxiety, impairment due to substance use, and perceived social support. Support persons predictors included their attitudes toward buprenorphine from four statements (e.g. "Buprenorphine is just replacing one drug for another") and communication using two items (e.g. comfort and effectiveness discussing substance use).Results: More stigmatizing attitudes, such as believing patients should quit on their own without medication, were associated with increased patient substance use-related impairment (F = 4.53, p = .01). Effective communication was associated with lower patient depression (F = 10.15, p < .001), anxiety (F = 4.73, p = .001), lower impairment (F = 6.46, p < .001), and higher perceived social support (F = 3.68, p = .007).Conclusions: This study highlights how support person attitudes and communication dynamics significantly affect the mental health and impairment of individuals receiving buprenorphine treatment. Interventions that reduce stigma and promote effective communication between patients and their loved ones could enhance treatment outcomes and overall well-being among patients with OUD.
背景:虽然社会支持有利于治疗阿片类药物使用障碍的患者,但目前尚不清楚社会支持如何影响患者的预后。目的:本研究探讨支持人对丁丙诺啡的态度和他们对物质使用的沟通与接受丁丙诺啡治疗的患者的幸福感之间的关系。方法:我们分析219例丁丙诺啡患者(40%为女性)及其支持人员(72%为女性)的横断面基线数据。研究人员从五个社区卫生中心招募了患者,并要求他们提名一名支持人员。患者结果包括抑郁症状、焦虑、药物使用损害和感知到的社会支持。支持人员的预测因子包括他们对丁丙诺啡的态度。“丁丙诺啡只是用一种药物代替另一种药物”)以及使用两个项目(例如讨论药物使用的舒适度和有效性)进行交流。结果:更多的污名化态度,如认为患者应该在没有药物的情况下自行戒烟,与患者物质使用相关损害的增加有关(F = 4.53, p = 0.01)。有效的沟通与患者抑郁程度降低(F = 10.15, p p = .001)、损害程度降低(F = 6.46, p p = .007)相关。结论:本研究强调了支持人态度和沟通动态如何显著影响接受丁丙诺啡治疗的个体的心理健康和损害。减少耻辱感和促进患者与亲人之间有效沟通的干预措施可以提高OUD患者的治疗效果和整体幸福感。
期刊介绍:
The American Journal of Drug and Alcohol Abuse (AJDAA) is an international journal published six times per year and provides an important and stimulating venue for the exchange of ideas between the researchers working in diverse areas, including public policy, epidemiology, neurobiology, and the treatment of addictive disorders. AJDAA includes a wide range of translational research, covering preclinical and clinical aspects of the field. AJDAA covers these topics with focused data presentations and authoritative reviews of timely developments in our field. Manuscripts exploring addictions other than substance use disorders are encouraged. Reviews and Perspectives of emerging fields are given priority consideration.
Areas of particular interest include: public health policy; novel research methodologies; human and animal pharmacology; human translational studies, including neuroimaging; pharmacological and behavioral treatments; new modalities of care; molecular and family genetic studies; medicinal use of substances traditionally considered substances of abuse.